Adsouth Partners (ASPR): Wow! Never thought I would see this trad...

Wow! Never thought I would see this trade

HSR · 2012-02-16T20:50:42.8470000Z

Wow! Never thought I would see this trade ever again. Wonder what's going on. A big trade of 20,334 shares.

Play Episode

7min

Proactive - Interviews for investors

Greatland Gold's Shaun Day on Telfer Reserve & Havieron expansion plans

Greatland Gold PLC managing director Shaun Day talked with Proactive about the company’s updated ore reserve for the Telfer gold-copper mine and its forward-looking development strategy. Day outlined the release of a 712,000-ounce gold and 23,000-tonne copper ore reserve for Telfer, achieved just five months post-acquisition. This comes on the heels of a 3.2 million ounce resource estimate, collectively taking the total resource base, including Havieron, beyond 10.0 million ounces. “This is really built on the back of Michael Thompson and his team,” Day said, noting the speed and scale of the update. He emphasized that the reserve confirms continuity at Telfer as Havieron ramps up, avoiding any production gap. Day also discussed the two-year dual-train production outlook through FY27 and emphasized the production and cost benefits expected once Havieron, a significantly higher-grade and lower-cost asset, is integrated. An updated feasibility study aims to expand Havieron from 2.8 to 4–4.5 million tonnes per annum, potentially via conveyor infrastructure to enhance economics and ESG performance. Looking ahead, Day pointed to opportunities to extend mine life, increase drilling, and develop the West Dome Underground. “The team is really humming right now,” he said. Visit Proactive’s YouTube channel for more videos like this. Don’t forget to like this video, subscribe to the channel, and enable notifications for future content. #GreatlandGold #ShaunDay #TelferMine #Havieron #GoldMining #CopperMining #MiningUpdate #FeasibilityStudy #ASXMining #MineralResources #GoldInvesting #MiningDevelopment #ResourceUpdate

Proactive - Interviews for investors

Tonix Pharmaceuticals launches :TONIX ONE™ A digital breakthrough in migraine management

Tonix Pharmaceuticals is making waves in the healthcare industry with the launch of TONIX ONE™ a fully integrated digital platform designed to empower migraine patients with better tools for understanding and managing their condition. In an exclusive discussion with Proactive’s Steve Darling, Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, unveiled the platform’s innovative features and strategic partnerships aimed at transforming migraine care. By collaborating with UpScript Telemedicine, ProModRx, Blink Health, and a leading mobile application specializing in disease tracking, symptom reporting, and management, TONIX ONE offers a comprehensive, patient-centric solution. Dr. Lederman highlighted that TONIX ONE™ beyond conventional migraine education by providing critical insights into the limitations of oral medications, which can sometimes result in delayed or ineffective symptom relief. The platform bridges the gap between patients and healthcare providers, offering direct access to migraine specialists via telehealth consultations and seamless e-prescription requests—ensuring a faster, more effective pathway to treatment. With this initiative, Tonix Pharmaceuticals aims to not only educate and empower patients in their treatment journey but also eliminate the barriers to care that many migraine sufferers face. By integrating advanced digital health solutions,TONIX ONE™ stands at the forefront of a new era in migraine management, offering patients greater control over their health and well-being. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #MigraineTreatment #TonixOne #DigitalHealth #Telemedicine #ZembraceSymTouch #Tosymra #HealthcareInnovation #PharmaNews #ProactiveInvestors

Proactive - Interviews for investors

Ananda Pharma adds former GW Pharmaceuticals executive as strategic advisor, advances MRX1

Ananda Pharma Plc finance director Jeremy Sturgess-Smith talked with Proactive's Stephen Gunnion about the appointment of Chris Tovey as a strategic advisor. Tovey brings significant experience from his time as chief operating officer at GW Pharmaceuticals and later Jazz Pharmaceuticals. According to Sturgess-Smith: “He’s going to bring all that experience to Ananda,” helping guide the company through its regulatory path and corporate development. Sturgess-Smith also touched on Ananda securing ethics approval to begin its first human trial of MRX1, a key milestone for the company’s therapeutic pipeline. He noted this was the first ethics approval of its kind for any Ananda trial, with recruitment expected to begin shortly in Australia. “It’s very, very exciting to have that ethics approval in the bag,” he said. Looking ahead, the company also expects ethics approvals for studies into chemotherapy-induced peripheral neuropathy and endometriosis in the next six months. For more interviews and updates, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe, and hit the notification bell to stay informed.** #AnandaPharma #MRX1Trial #ClinicalTrials #CannabinoidMedicine #BiotechNews #PharmaceuticalInnovation #EthicsApproval #GWPharma #DrugDevelopment #Epidiolex #HealthInnovation #ProactiveInvestors

Proactive - Interviews for investors

Scancell fast-tracks melanoma study with NHS

Scancell Holdings PLC CEO Phillip L’Huillier joined Proactive's Stephen Gunnion with details of the company’s partnership with the NHS Cancer Vaccine Launchpad to accelerate patient recruitment for its SCOPE study evaluating the iSCIB1+ DNA cancer vaccine. L’Huillier described the deal as “a very positive endorsement for Scancell and for the medicines that we are developing,” noting that the therapy is showing promise in delivering long-term immune control in advanced melanoma patients. The NHS collaboration enables hospitals to more quickly access and offer the iSCIB1+ therapy as part of the trial, making Scancell the first UK company to partner with the platform and the first to offer a DNA cancer vaccine through it. He explained that the vaccine is given alongside checkpoint inhibitors, currently standard care, to boost response rates and prolong efficacy, especially where standard therapy alone sees limited, short-lived results. L’Huillier confirmed multiple SCOPE study data readouts are expected in 2025, with a larger development phase targeted for 2026. The company is also progressing its Modi-1 peptide vaccine and aims to further develop its GlyMab antibody platform, including the SC134 programme for small cell lung cancer. L’Huillier said his CEO priorities include sticking to development timelines, building strategic partnerships, and preparing the organisation for future phases. For more exclusive biotech interviews, visit Proactive's YouTube channel. Don't forget to like the video, subscribe to the channel, and enable notifications for future updates. #Scancell #CancerVaccine #BiotechNews #iSCIB1 #MelanomaResearch #NHSPartnership #DNAImmunotherapy #Modi1 #ClinicalTrials #OncologyInnovation #InvestorUpdate #ProactiveInvestors

Followers	1
Posts	353
Boards Moderated	0
Alias Born	01/18/2010

Volume:	-
Day Range:
Bid:	0.0006
Ask:	0.0006
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

ASPR Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free